DEA’s Cannabis Catch-22: Expand Research, Maintain Criminality
Late last summer, the Drug Enforcement Administration (DEA) adopted a new policy designed to foster an increase in medicinal cannabis research. The Administration’s decision opens doors to a larger number of marijuana suppliers qualified to produce cannabis for scientific study, a shift that will arguably lead to broader and more comprehensive study of a drug which, despite widespread medical use throughout the country, remains highly controversial.